PDCD1 and neoplasm: Similarly, using spatial protein profiling, a study of 67 advanced NSCLC samples from patients treated with anti-PD-1 therapy showed expression of VISTA and CD127 in the tumor compartment as markers of immunotherapy resistance, while high CD56 and CD4 were associated with both overall and progression-free survival [75].